TSCAN THERAPEUTICS, INC. Operating Lease Liability
TSCAN THERAPEUTICS, INC. (TCRX) had Operating Lease Liability of $61.60 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-04
- 2025-12-31: Operating Lease, Liability $61.60M.
- 2024-12-31: Operating Lease, Liability $65.31M.
- 2024-10-28: Operating Lease, Liability $6.10M.
- 2023-12-31: Operating Lease, Liability $62.39M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $61.60M 10-K · filed 2026-03-04 |
| 2024-12-31 | $65.31M 10-K · filed 2026-03-04 |
| 2024-10-28 | $6.10M 10-K · filed 2026-03-04 |
| 2023-12-31 | $62.39M 10-K · filed 2025-03-05 |
| 2023-11-08 | $6.20M 10-K · filed 2025-03-05 |
| 2022-12-31 | $56.69M 10-K · filed 2024-03-06 |
| 2022-10-28 | $53.50M 10-K · filed 2023-03-08 |
| 2021-12-31 | $6.04M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |